{"id":36019,"date":"2025-10-21T11:01:56","date_gmt":"2025-10-21T09:01:56","guid":{"rendered":"https:\/\/ggba.swiss\/?p=36019"},"modified":"2025-10-21T11:09:11","modified_gmt":"2025-10-21T09:09:11","slug":"adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/","title":{"rendered":"ADC Therapeutics raises USD 60 million to strengthen oncology portfolio"},"content":{"rendered":"\n

ADC Therapeutics<\/a>, a global pioneer in the field of antibody-drug conjugates (ADCs), has announced a USD 60 million private investment in public equity (PIPE) financing to support its next phase of growth. Based at the Biop\u00f4le life sciences campus<\/a> in Lausanne, the company is advancing a portfolio of targeted oncology therapies designed to improve outcomes for patients with difficult-to-treat cancers.<\/p>\n\n\n\n

The financing round is led by TCGX<\/a>, with participation from Redmile Group<\/a> and other existing investors. ADC Therapeutics will issue 11.3 million common shares at USD 4.00 per share and 3.8 million pre-funded warrants at USD 3.90 each. The transaction, expected to close on October 27, 2025, will provide the company with approximately USD 57.6 million in net proceeds after expenses.<\/p>\n\n\n\n

The funds will be used to support the commercial expansion of ZYNLONTA\u00ae<\/a>, ADC Therapeutics\u2019 FDA- and EMA-approved treatment for relapsed or refractory large B-cell lymphoma, and to strengthen the company\u2019s financial position ahead of a potential relaunch in 2027. \u201cThis financing enhances our ability to prepare for and execute the potential relaunch of ZYNLONTA and further strengthens our balance sheet,\u201d said Ameet Mallik, CEO of ADC Therapeutics. \u201cWe believe we are well-positioned to accelerate our trajectory towards long-term sustainable growth.\u201d<\/p>\n\n\n\n

A hub for advanced cancer research and precision medicine<\/h4>\n\n\n\n

ZYNLONTA, the company\u2019s lead product, is the first and only CD19-directed ADC approved for adult patients who have received two or more prior lines of therapy. By combining an antibody targeting B-cell surface proteins with a potent cytotoxic payload, ZYNLONTA delivers targeted cancer cell destruction while minimizing off-target effects.<\/p>\n\n\n\n

Founded in 2011 and headquartered in the canton of Vaud, ADC Therapeutics exemplifies Western Switzerland\u2019s strength in oncology innovation. Its presence within the Biop\u00f4le ecosystem, home to a growing cluster of biotech and medtech companies, continues to reinforce the region\u2019s reputation as a European hub for advanced cancer research and precision medicine.<\/p>\n","protected":false},"excerpt":{"rendered":"

Lausanne-based biotech ADC Therapeutics has secured USD 60 million in new financing to expand commercialization of its cancer treatment ZYNLONTA.<\/p>\n","protected":false},"author":6,"featured_media":36027,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,894,881,890,883,886,901],"class_list":["post-36019","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-financing","tag-headquarters","tag-healthcare","tag-oncology","tag-rd","tag-technology-park"],"acf":[],"yoast_head":"\nADC Therapeutics raises USD 60 million | GGBa<\/title>\n<meta name=\"description\" content=\"ADC Therapeutics has secured USD 60 million in new financing to expand commercialization of its cancer treatment ZYNLONTA.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADC Therapeutics raises USD 60 million | GGBa\" \/>\n<meta property=\"og:description\" content=\"ADC Therapeutics has secured USD 60 million in new financing to expand commercialization of its cancer treatment ZYNLONTA.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-21T09:01:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-21T09:09:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/ADC-Therapeutics-2025-1180x811-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1520\" \/>\n\t<meta property=\"og:image:height\" content=\"936\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"ADC Therapeutics raises USD 60 million to strengthen oncology portfolio\",\"datePublished\":\"2025-10-21T09:01:56+00:00\",\"dateModified\":\"2025-10-21T09:09:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/\"},\"wordCount\":317,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/ADC-Therapeutics-2025-1180x811-1.png\",\"keywords\":[\"Biotech\",\"Financing\",\"Headquarters\",\"Healthcare\",\"Oncology\",\"R&D\",\"Technology Park\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/\",\"url\":\"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/\",\"name\":\"ADC Therapeutics raises USD 60 million | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/ADC-Therapeutics-2025-1180x811-1.png\",\"datePublished\":\"2025-10-21T09:01:56+00:00\",\"dateModified\":\"2025-10-21T09:09:11+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"ADC Therapeutics has secured USD 60 million in new financing to expand commercialization of its cancer treatment ZYNLONTA.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/ADC-Therapeutics-2025-1180x811-1.png\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/ADC-Therapeutics-2025-1180x811-1.png\",\"width\":1520,\"height\":936,\"caption\":\"ADC Therapeutics\u2019 antibody-drug conjugates (ADCs) deliver targeted cancer therapy by combining monoclonal antibodies with potent cytotoxic agents. | \u00a9 ADC Therapeutics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADC Therapeutics raises USD 60 million to strengthen oncology portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ADC Therapeutics raises USD 60 million | GGBa","description":"ADC Therapeutics has secured USD 60 million in new financing to expand commercialization of its cancer treatment ZYNLONTA.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/","og_locale":"en_US","og_type":"article","og_title":"ADC Therapeutics raises USD 60 million | GGBa","og_description":"ADC Therapeutics has secured USD 60 million in new financing to expand commercialization of its cancer treatment ZYNLONTA.","og_url":"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-10-21T09:01:56+00:00","article_modified_time":"2025-10-21T09:09:11+00:00","og_image":[{"width":1520,"height":936,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/ADC-Therapeutics-2025-1180x811-1.png","type":"image\/png"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"ADC Therapeutics raises USD 60 million to strengthen oncology portfolio","datePublished":"2025-10-21T09:01:56+00:00","dateModified":"2025-10-21T09:09:11+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/"},"wordCount":317,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/ADC-Therapeutics-2025-1180x811-1.png","keywords":["Biotech","Financing","Headquarters","Healthcare","Oncology","R&D","Technology Park"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/","url":"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/","name":"ADC Therapeutics raises USD 60 million | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/ADC-Therapeutics-2025-1180x811-1.png","datePublished":"2025-10-21T09:01:56+00:00","dateModified":"2025-10-21T09:09:11+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"ADC Therapeutics has secured USD 60 million in new financing to expand commercialization of its cancer treatment ZYNLONTA.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/ADC-Therapeutics-2025-1180x811-1.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/ADC-Therapeutics-2025-1180x811-1.png","width":1520,"height":936,"caption":"ADC Therapeutics\u2019 antibody-drug conjugates (ADCs) deliver targeted cancer therapy by combining monoclonal antibodies with potent cytotoxic agents. | \u00a9 ADC Therapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/adc-therapeutics-raises-usd-60-million-to-strengthen-oncology-portfolio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"ADC Therapeutics raises USD 60 million to strengthen oncology portfolio"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/36019","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=36019"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/36019\/revisions"}],"predecessor-version":[{"id":36023,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/36019\/revisions\/36023"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/36027"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=36019"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=36019"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=36019"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}